Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, Nishide T, Okamura K, Saito Y, Teramoto T
Maizuru Kyosai Hospital, Kyoto, Japan.
Atherosclerosis. 1992 Jul;95(1):1-13. doi: 10.1016/0021-9150(92)90170-l.
The purpose of the LDL-Apheresis Regression Study (LARS) group, which included 13 institutions in Japan, was to investigate the effects on coronary atherosclerosis of LDL-apheresis combined with cholesterol-lowering drugs. Changes in coronary artery stenosis were assessed angiographically in 37 patients with familial hypercholesterolemia (7 homozygotes and 25 heterozygotes) and hypercholesterolemia which had not been defined as familial hypercholesterolemia (5 patients) by visual judgement and computer analysis. Definite regression was observed in 14 cases, including 4 homozygotes and 10 heterozygotes and others. Regression occurred as often in patients with severe coronary artery disease (2 or more vessel disease) as in those having less severe disease. Our results encourage initiation of aggressive cholesterol-lowering therapy to produce regression of coronary atherosclerosis in FH patients at high risk for cardiovascular events.
低密度脂蛋白分离单采回归研究（LARS）小组由日本的13家机构组成，其目的是研究低密度脂蛋白分离单采联合降胆固醇药物对冠状动脉粥样硬化的影响。通过视觉判断和计算机分析，对37例家族性高胆固醇血症患者（7例纯合子和25例杂合子）以及未被定义为家族性高胆固醇血症的高胆固醇血症患者（5例）的冠状动脉狭窄变化进行了血管造影评估。在14例患者中观察到明确的病变消退，包括4例纯合子、10例杂合子和其他患者。严重冠状动脉疾病（两支或更多支血管病变）患者的病变消退情况与病情较轻患者的相同。我们的研究结果鼓励对心血管事件高危的家族性高胆固醇血症患者积极开展降胆固醇治疗，以促使冠状动脉粥样硬化消退。
